BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bordeaux Neurocampus - ECPv4.9.10//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Bordeaux Neurocampus
X-ORIGINAL-URL:https://www.bordeaux-neurocampus.fr/en/
X-WR-CALDESC:Events for Bordeaux Neurocampus
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20211203T140000
DTEND;TZID=Europe/Paris:20211203T140000
DTSTAMP:20260424T224649
CREATED:20210825T160704Z
LAST-MODIFIED:20211015T125218Z
UID:138068-1638540000-1638540000@www.bordeaux-neurocampus.fr
SUMMARY:Thesis defense - Anthony Cunha
DESCRIPTION:\n	\n		\n			Venue : Auditorium du Centre Broca Nouvelle-Aquitaine \nDefense in french \n\nTitle\nConception\, synthesis and formulation of original nucleolipids for the targeting of neurons of interest in Parkinson’s disease. \n(Conception\, synthèse et formulation de nucléolipides originaux pour le ciblage de neurones d’intérêt dans le cadre de la maladie de Parkinson.) \nAbstract\nDue to their prevalence\, high societal cost and lack of chronic treatment\, the search for new treatments for neurodegenerative diseases is one of the major challenges today. Lysosomal impairment may be a common factor in neurodegeneration and the restoration of the lysosomal function is a global mechanism of action to fight against all these pathologies. Nevertheless\, the blood-brain barrier (BBB) passage allowing the delivery of therapeutic agents to target neurons\, remains a major challenge to validate this approach. In this context\, this work consisted in designing and developing several glyconucleolipids (GNLs) nanovectors as cargo system\, carrying trehalose a therapeutic agent. They were then formulated either in solid lipid nanoparticles (SLN) or encapsulated into PLGA nanoparticles (NPs)\, which have already demonstrated their usefulness in crossing the BBB. The ability of these nanoformulations to cross biological membranes and induce autophagy for Parkinson’s disease treatment was evaluated in vitro. \nPublications\n\nCunha\, Anthony\, Gaubert\, Alexandra\, Latxague\, Laurent\, Dehay\, Benjamin. « PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases ». Pharmaceutics\, (2021)\, 13\, 1042. https://doi.org/10.3390/pharmaceutics13071042\nCunha\, A.; Prévot\, G.; Mousli\, Y.; Barthélémy\, P.; Crauste-Manciet\, S.; Dehay\, B.;  Desvergnes\, V. Synthesis and Intracellular Uptake of Rhodamine–Nucleolipid Conjugates into a Nanoemulsion Vehicle. ACS Omega 2020 5 (11)\, 5815-5823 https://doi.org/10.1021/acsomega.9b03992\nComposition du jury : Audrey Esclatine\, Suzanne Peyrottes\, Philippe Barthélémy\, Laurent Latxague\, Benjamin Dehay\, Alexandra Gaubert\n\n\n		\n	\n\n	\n		\n			Jury\n\nAudrey Esclatine\nSuzanne Peyrottes\nPhilippe Barthélémy\nPhilippe Liénard\nLaurent Latxague\nBenjamin Dehay\nAlexandra Gaubert\n\n\n		\n	\n\n	\n		\n			 \nAnthony Cunha\nTeam Pathophysiology of parkinsonian syndromes\nIMN \n\n		\n	\n\n	\n		\n			Thesis supervisors: Dr. Benjamin Dehay (IMN) and Dr. Laurent Latxague (ChemBioPharm) \n\n		\n	\n\n
URL:https://www.bordeaux-neurocampus.fr/en/event/thesis-defense-anthony-cunha/
CATEGORIES:Thesis
END:VEVENT
END:VCALENDAR